{"id":499527,"date":"2021-05-27T16:18:56","date_gmt":"2021-05-27T20:18:56","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference\/"},"modified":"2021-05-27T16:18:56","modified_gmt":"2021-05-27T20:18:56","slug":"anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference\/","title":{"rendered":"AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>SAN DIEGO, May  27, 2021  (GLOBE NEWSWIRE) &#8212; AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 1:30 p.m. ET. The conference will be conducted virtually, and the audio presentation will be available via: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tBeJMYNsUjuV58Lvubia4hRAJxj2wZSYlioRgEMvZ3ycNsPYRD6NYnmzGehi2coQWVdsGngtgsGwDHDnTNkUB3GKbp1p3wFHowJYuakbDXLGX_uLqPKI-OiluXAuLJp7Q8UbsIPjzwz2acmrWqIikg==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/wsw.com\/webcast\/jeff174\/anab\/1811646<\/a>.<\/p>\n<p>A live webcast of the presentation will also be available through the investor section of the AnaptysBio website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tBeJMYNsUjuV58Lvubia4uM9hEmqJYK6b-g-YGxl_uyJOHHpwjbSqxehGRkEiJvmwT37UCvKL8u1XHPacj51lcpcKP-5J6QIi7mgCLeXRQNTqx-0EZkwjMcuXa8BhL-A\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/ir.anaptysbio.com\/events<\/a>. A replay of the webcast will be available for 60 days following the event.<\/p>\n<p>\n        <strong>About AnaptysBio<\/strong>\n      <\/p>\n<p>AnaptysBio\u00a0is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation. The Company\u2019s proprietary anti-inflammatory pipeline includes imsidolimab, its anti-IL-36R antibody, previously referred to as ANB019, for the treatment of dermatological inflammatory diseases, including generalized pustular psoriasis, or GPP, EGFRi skin toxicity, ichthyosis, hidradenitis suppurativa and acne; its anti-PD-1 agonist program, ANB030, for treatment of certain autoimmune diseases where immune checkpoint receptors are insufficiently activated; and its BTLA modulator program, ANB032, which is broadly applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. AnaptysBio\u2019s antibody pipeline has been developed using its proprietary somatic hypermutation, or SHM platform, which uses in vitro SHM for antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of competing antibody discovery technologies.\u00a0AnaptysBio\u00a0has also developed multiple therapeutic antibodies in an immuno-oncology collaboration with GSK, including an anti-PD-1 antagonist antibody (JEMPERLI (dostarlimab-gxly)), an anti-TIM-3 antagonist antibody (cobolimab, GSK4069889) and an anti-LAG-3 antagonist antibody (GSK4074386), and an inflammation collaboration with Bristol-Myers Squibb, including an anti-PD-1 checkpoint agonist antibody (CC-90006) currently in clinical development.<\/p>\n<p>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Dennis Mulroy<br \/>AnaptysBio, Inc.<br \/>858.732.0201<br \/>dmulroy@anaptysbio.com<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDU5MyM0MjA0NjgxIzIwMjAxMjY=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/a5b2ae5d-d35c-45d1-84d9-cc38071e8031\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, May 27, 2021 (GLOBE NEWSWIRE) &#8212; AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 1:30 p.m. ET. The conference will be conducted virtually, and the audio presentation will be available via: https:\/\/wsw.com\/webcast\/jeff174\/anab\/1811646. A live webcast of the presentation will also be available through the investor section of the AnaptysBio website at https:\/\/ir.anaptysbio.com\/events. A replay of the webcast will be available for 60 days following the event. About AnaptysBio AnaptysBio\u00a0is a clinical-stage biotechnology company developing first-in-class antibody product &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-499527","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, May 27, 2021 (GLOBE NEWSWIRE) &#8212; AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 1:30 p.m. ET. The conference will be conducted virtually, and the audio presentation will be available via: https:\/\/wsw.com\/webcast\/jeff174\/anab\/1811646. A live webcast of the presentation will also be available through the investor section of the AnaptysBio website at https:\/\/ir.anaptysbio.com\/events. A replay of the webcast will be available for 60 days following the event. About AnaptysBio AnaptysBio\u00a0is a clinical-stage biotechnology company developing first-in-class antibody product &hellip; Continue reading &quot;AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-27T20:18:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDU5MyM0MjA0NjgxIzIwMjAxMjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference\",\"datePublished\":\"2021-05-27T20:18:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference\\\/\"},\"wordCount\":321,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NDU5MyM0MjA0NjgxIzIwMjAxMjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference\\\/\",\"name\":\"AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NDU5MyM0MjA0NjgxIzIwMjAxMjY=\",\"datePublished\":\"2021-05-27T20:18:56+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NDU5MyM0MjA0NjgxIzIwMjAxMjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NDU5MyM0MjA0NjgxIzIwMjAxMjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference - Market Newsdesk","og_description":"SAN DIEGO, May 27, 2021 (GLOBE NEWSWIRE) &#8212; AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 1:30 p.m. ET. The conference will be conducted virtually, and the audio presentation will be available via: https:\/\/wsw.com\/webcast\/jeff174\/anab\/1811646. A live webcast of the presentation will also be available through the investor section of the AnaptysBio website at https:\/\/ir.anaptysbio.com\/events. A replay of the webcast will be available for 60 days following the event. About AnaptysBio AnaptysBio\u00a0is a clinical-stage biotechnology company developing first-in-class antibody product &hellip; Continue reading \"AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-05-27T20:18:56+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDU5MyM0MjA0NjgxIzIwMjAxMjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference","datePublished":"2021-05-27T20:18:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference\/"},"wordCount":321,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDU5MyM0MjA0NjgxIzIwMjAxMjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference\/","name":"AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDU5MyM0MjA0NjgxIzIwMjAxMjY=","datePublished":"2021-05-27T20:18:56+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDU5MyM0MjA0NjgxIzIwMjAxMjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDU5MyM0MjA0NjgxIzIwMjAxMjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/499527","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=499527"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/499527\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=499527"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=499527"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=499527"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}